BIOMAT Database Logo BIOMAT Database Logo

Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation. 1993

D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Department of Internal Medicine, Ulm University Hospital, Germany.

We investigated a case of graft rejection after in vivo/ex vivo T-depleted BMT in a patient who had received a HVG-matched, GVH one locus-mismatched, MLC-negative graft from his cousin. In vivo/ex vivo T cell depletion was performed with Campath 1G (CP1G) and Campath 1M (CP1M), respectively. We identified a failure of CP1G to eradicate a CDw52- (Campath-negative) host T cell population as the main cause of treatment failure. The analysis also suggests that significant host-versus-donor reactivity prior to transplant, as detected by limiting dilution analysis, also contributed to graft rejection. The rejecting T cells were bifunctional in that they showed cytotoxic activity and were capable of inhibiting haemopoietic progenitor growth by producing inhibitory lymphokines.

UI MeSH Term Description Entries
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008297 Male Males
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074301 CD52 Antigen A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB). CD52 Protein,CDw52 Antigen,Cambridge Pathology 1 Antigen,Campath-1 Antigen,Campath-1 Receptor,Campath-1H Antigen,HLA-Bw52,HLA-Bw52 Antigen,Lymphocyte Antigen CD52,Lymphocyte Antigen CDw52,CD52, Lymphocyte Antigen,CDw52, Lymphocyte Antigen,Campath 1 Antigen,Campath 1 Receptor,Campath 1H Antigen,HLA Bw52,HLA Bw52 Antigen

Related Publications

D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation.
November 1996, Bone marrow transplantation,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation.
June 1986, British journal of haematology,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Graft rejection after T-cell depleted marrow transplantation: role of fractionated irradiation.
April 1987, British journal of haematology,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Host-vs-graft and graft-vs-host reactivity and immune reconstitution after T-depleted allogeneic bone marrow transplantation.
September 1992, Pharmacological research,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Characterization of acute bone marrow graft rejection in T cell-depleted, partially mismatched related donor bone marrow transplantation.
December 1995, Experimental hematology,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Graft rejection following T lymphocyte depleted bone marrow transplantation with two different TBI regimens.
February 1987, British journal of haematology,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism.
November 1989, Blood,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
April 1992, Bone marrow transplantation,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells.
April 2000, Transplantation,
D Bunjes, and M Theobald, and M Wiesneth, and H Schrezenmeier, and T Hoffmann, and B Hertenstein, and R Arnold, and H Heimpel
CD5-positive B cells after T cell depleted bone marrow transplantation.
June 1987, Clinical and experimental immunology,
Copied contents to your clipboard!